Home/Insulet/Jim Hollingshead, Ph.D.
JH

Jim Hollingshead, Ph.D.

President and Chief Executive Officer

Insulet

Insulet Pipeline

DrugIndicationPhase
Omnipod 5 Type 2 ExpansionType 2 Diabetes (Adults)Commercial
Omnipod 5 International RolloutType 1 & Type 2 DiabetesCommercial
Next-Gen Hardware/SoftwareDiabetes ManagementR&D
CGM Ecosystem IntegrationDiabetes ManagementDevelopment/Regulatory